Tag: PD-(L)1 Bispecific Antibodies

In recent years, immune checkpoint inhibitors (ICIs) have emerged as a significant breakthrough in cancer therapy, reshaping traditional treatment paradigms. PD-1/PD-L1 pathway inhibitors have been...